Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shihui Hu

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Cancer Medicine|March 11, 2022
Heterogeneity derived from <sup>18</sup> F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patientsYizhao Xie, Cheng Liu, Yannan Zhao, et al.
Frontiers in Endocrinology|December 6, 2024
Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trialsShihui Hu, Yannan Zhao, Yizhao Xie, et al.
Therapeutic Advances in Medical Oncology|December 18, 2023
ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumorsShuhui You, Yizhao Xie, Mengjing Ji, et al.
Cancers|July 27, 2022
Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by <sup>18</sup>F-FES PETYizhao Xie, Xinyue Du, Yannan Zhao, et al.
BMC Cancer|November 3, 2021
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastasesYizhao Xie, Chengcheng Gong, Jian Zhang, et al.
Therapeutic Advances in Medical Oncology|July 22, 2021
Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective studyYannan Zhao, Ning Xie, Wei Li, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cancer Medicine|March 11, 2022
Heterogeneity derived from <sup>18</sup> F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patientsYizhao Xie, Cheng Liu, Yannan Zhao, et al.
Frontiers in Endocrinology|December 6, 2024
Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trialsShihui Hu, Yannan Zhao, Yizhao Xie, et al.
Therapeutic Advances in Medical Oncology|December 18, 2023
ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumorsShuhui You, Yizhao Xie, Mengjing Ji, et al.
Cancers|July 27, 2022
Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by <sup>18</sup>F-FES PETYizhao Xie, Xinyue Du, Yannan Zhao, et al.
BMC Cancer|November 3, 2021
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastasesYizhao Xie, Chengcheng Gong, Jian Zhang, et al.
Therapeutic Advances in Medical Oncology|July 22, 2021
Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective studyYannan Zhao, Ning Xie, Wei Li, et al.
Pageof 2